Stockreport

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]

Atea Pharmaceuticals, Inc. - common stock  (AVIR) 
PDF Enrollment in Phase 3 SUNRISE-3 Study Has Surpassed 1,400 COVID-19 Patients in Monotherapy Population; Two Interim Analyses by Independent Data Safety Monitoring Board [Read more]